Summary of the technology
New IgG antibody suitable for specific agglutination of erythrocytes, particulary for blood typing. The unique IgG3 antibody Miraculum may be a valuable, high-quality, next generation blood typing reagent with extended shelf life. It does not lose its property after freezing. Its production is very efficient and can be more profitable compared to currently used IgM-class antibody.
The invention consists in conversion of any non-agglutinating monoclonal antibody that recognizes an antigen on the surface of human erythrocytes into agglutinating molecule. The antibodies obtained in this way can be much more useful than IgM antibodies, which are currently used in agglutination assays.
New and innovative aspects
Determination of blood group typically is carried out using hemagglutination. Antibodies used woldwide for the diagnostics of blood groups belong to IgM class. Although antibodies of IgM class efficiently induce agglutination, they are unstable, tend to aggregate and quickly lose their agglutinating activity. Antibodies of IgG class, which are very stable and resistant to temperature changes, including freezing, generally do not agglutinate red blood cells.
The new invention of the Jagiellonian University provides monoclonal antibody of class IgG3 Miraculum for detecion of antigen B from ABO group system in human (antibodies for other blood groups are under development). The invention also includes a new method of conversion of any non-agglutinating monoclonal antibody that recognizes an antigen on the surface of human erythrocytes into agglutinating molecule.
Main advantages of its use
A comparison of Miraculum with IgM antibodies, which are currently used in serological diagnostics, revealed that:
- IgG3 antibodies are extremely stable - they retain full activity for at least five days at 42°C, while IgM antibodies begin to lose their functionality after 24 h;
- molar efficiency of production of IgG3 is more than fifteen times better than IgM antibodies;
- IgG3 antibodies can be easily purified using standard chromatographic techniques;
- IgG3 can be stored in a frozen state, which is not possible in the case of IgM antibodies.
The antibodies obtained by the new method are able to agglutinate erythrocytes, they are also much more useful than IgM antibodies currently used in agglutination assays.
A new IgG antibody suitable for specific agglutination of erythocytes, particularly for blood typing. The unique IgG3 antiobody Miraculum developed by researchers at the Jagiellonian University agglutinates red blood cells expressing antigen B. Miraculum may be a valuable, high-quality, next generation blood typing reagent with extended shelf life. Miraculum does not lose its property after freezing. Its production is very efficient and can be more profitable compared to currently used IgM-class antibody.
A new method consists in conversion of any non-agglutinating monoclonal antibody that recognizes an antigen on the surface of human erythoryctes into agglutinating molecule. The conversion is possible due to rearrangemenent of a genetic sequence coding for the non-agglutinating antibody.
- Monoclonal antibody Miraculum and preparation method of agglutinating monoclonal antibodies are intended for production of monoclonal reagents for serological diagnostics in vitro - application in biotechnology.
Intellectual property status
Monoclonal antibody Miraculum and preparation method agglutinating monoclonal antibodies is the subject of patent application (PCT patent application - September 2015).
Current development status
Working prototype or samples ready for testing.
Desired business relationship
- commercial agreement
- licence aggreement
- technical cooperation – further development
- technical cooperation – adaptation to specific needs
About Centre Technology Transfer CITTRU
Technology Transfer Office from PolandCentre Technology Transfer CITTRU
Centre for Innovation, Technology Transfer and University Development (CITTRU) is a part of Jagiellonian University, whose role is to promote university research, to support innovation and to create cooperation with the business. CITTRU main task is to offer the scientific achievements of the Jagiellonian University in the market by providing legal protection, licensing, sale of intellectual property rights, creation of academic business, coordination of company-ordered research projects, etc. Currently promoted technologies are mainly focused on new materials science, pharmacology and medical technology. Inventions offered by Jagiellonian University are promoted and awarded during numerous exhibitions, e.g. 58th International Exhibition of Innovation, Research and New Technologies INNOVA (BRUSSELS 2009), 38th International Exhibition of Invention New Techniques & Products (Geneva 2010) or 24th International exhibition of environmental equipment, technologies and services POLLUTEC (Paris 2009).